Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 /CenExel is pleased to announce its partnership with Metsera, Inc.
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com . A replay of the webcast will be available for ...
Metsera's lead injectable GLP-1 drug has already demonstrated significant weight loss and tolerability in a Phase 2 obesity trial. Cantor Fitzgerald's analysis suggests that this drug could ...
Guggenheim has initiated Metsera at buy saying that the ... excellent 12-week weight loss seen in a phase 2a trial, and an improved tolerability profile. "If 097i demonstrates acceptable ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果